talquetamab 
GtoPdb Ligand ID: 12240
|
Synonyms: JNJ-64407564 | JNJ64407564 | talquetamab-tgvs | Talvey®
talquetamab is an approved drug (FDA & EMA (2023))
Compound class:
Antibody
Comment: Talquetamab (JNJ-64407564) is a humanized, IgG4 bispecific monoclonal antibody that engages the orphan GPCR GPRC5D that's expressed on majority of malignant plasma cells from multiple myeloma (MM) patients and CD3ε on T cells [3]. It has amino acid substitutions in its Fc region to minimise binding to Fcγ receptors and antibody-directed effector functions. The peptide sequences for talquetamab's heavy and light chains are claimed in Janssen's patent US10562968B2 [1]. In preclinical studies talquetamab promoted immune killing of MM cells, including cells from patients with daratumumab-refractory disease [4].
|
| Bioactivity Comments |
| Talquetamab (JNJ-64407564) activates T cell-mediated cytotoxicity against GPRC5D-positive cells with EC50 of <1 nM in vitro [3]. |
| Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License